Results of the ezetimibe in prevention of cerebro- and cardiovascular events in middle- to high-risk, elderly (75 years old or over) patients with elevated LDL-cholesterol (EWTOPIA75) presented at the American Heart Association Scientific Sessions 2018 in Chicago show that ezetimibe reduced the rate of a first cardiac event — a composite of sudden cardiac death, myocardial infarction (MI), coronary revascularization, and stroke — more than diet alone in 75- to 104-year-old Japanese patients with elevated LDL-cholesterol (LDL-C) and a second risk factor.